Selio Medical Limited

Co-Founders Colm McGarvey & Dr. Garrett Ryan identified this large unmet clinical need during the BioInnovate Fellowship Programme at the National University of Galway (NUIG) & at the University College Cork (UCC). The project then spun-into Trinity College Dublin where it was de-risked with support from Enterprise Ireland.Selio Medical spun-out of Trinity College Dublin into a new facility located in the heart of Dublin, significantly expanding the team with the support from our international corporate investor, EIT Health and the European Innovation Council (EIC).

Selio Medical continues to develop our platform technology to improve the lives of lung cancer patients worldwide.Selio Medical adopts an unique approach by providing pneumothorax protection before the biopsy even takes place.The Selio Sealant System is a single use, prophylactic device, comprising a percutaneous delivery needle together with a novel biodegradable hydrogel sealant.Our proven patented technology seamlessly integrates with the current standard of care and enables the clinician to pre-seal the access route into the lung before the biopsy.The Selio Sealant System provides pneumothorax protection for the in-patient, thereby allowing the patient to safely return home on the same day as their procedure. This significantly improves the patient’s quality of care while preventing further treatment and costs.